WASHINGTON, Jan. 31 (Xinhua) -- The U.S. Food and Drug Administration on Friday approved Palforzia, the first drug treatment for peanut allergy for children aged four to 17 years old.
File photo: CGTN
"Palforzia provides an FDA-approved treatment option to help reduce the risk of these allergic reactions in children with peanut allergy," said Peter Marks, director of the FDA's Center for Biologics Evaluation and Research. Those who take Palforzia must continue to avoid peanuts in their diets.
Peanut allergy affects approximately one million children in the United States and only one out of five of these children will outgrow their allergy.
Palforzia is a powder manufactured from peanuts and packaged in pull-apart capsules and a sachet.
The powder is mixed with a small amount of semisolid food like yogurt, according to the FDA.
Palforzia is priced it at 890 U.S. dollars per month.